AB Science S.A. (0Q77.L)
EUR 0.87
(-6.75%)
EUR 0.87
(-6.75%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -13.42 Million EUR | 15.74% |
| 2022 | -15.93 Million EUR | -15.43% |
| 2021 | -13.8 Million EUR | 6.38% |
| 2020 | -14.74 Million EUR | 15.59% |
| 2019 | -17.47 Million EUR | 39.63% |
| 2018 | -28.94 Million EUR | -1.9% |
| 2017 | -28.4 Million EUR | 5.97% |
| 2016 | -30.2 Million EUR | -16.34% |
| 2015 | -25.96 Million EUR | -70.78% |
| 2014 | -15.2 Million EUR | -10.39% |
| 2013 | -13.77 Million EUR | -29.77% |
| 2012 | -10.61 Million EUR | -9.23% |
| 2011 | -9.71 Million EUR | -1.32% |
| 2010 | -9.58 Million EUR | -15.57% |
| 2009 | -8.29 Million EUR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -4.59 Million EUR | 0.0% |
| 2023 Q3 | -2.28 Million EUR | 79.04% |
| 2023 Q4 | -2.28 Million EUR | 0.0% |
| 2023 FY | -13.42 Million EUR | 15.74% |
| 2023 Q1 | -4.42 Million EUR | 50.52% |
| 2023 Q2 | -10.92 Million EUR | -146.85% |
| 2022 Q3 | -3.18 Million EUR | 71.03% |
| 2022 Q2 | -11 Million EUR | -130.12% |
| 2022 Q1 | -4.78 Million EUR | 50.23% |
| 2022 FY | -15.93 Million EUR | -15.43% |
| 2022 Q4 | -8.94 Million EUR | -180.56% |
| 2021 Q2 | -8.07 Million EUR | -167.25% |
| 2021 Q1 | -3.02 Million EUR | 68.02% |
| 2021 FY | -13.8 Million EUR | 6.38% |
| 2021 Q4 | -9.6 Million EUR | -147.37% |
| 2021 Q3 | -3.88 Million EUR | 51.88% |
| 2020 Q2 | -8.62 Million EUR | -150.0% |
| 2020 Q3 | -3.92 Million EUR | 54.45% |
| 2020 FY | -14.74 Million EUR | 15.59% |
| 2020 Q1 | -3.44 Million EUR | 59.54% |
| 2020 Q4 | -9.44 Million EUR | -140.47% |
| 2019 Q2 | -13.07 Million EUR | -147.19% |
| 2019 FY | -17.47 Million EUR | 39.63% |
| 2019 Q1 | -5.28 Million EUR | 28.28% |
| 2019 Q4 | -8.52 Million EUR | -147.16% |
| 2019 Q3 | -3.44 Million EUR | 73.63% |
| 2018 Q2 | -7.09 Million EUR | 0.0% |
| 2018 Q1 | -7.09 Million EUR | 3.43% |
| 2018 FY | -28.94 Million EUR | -1.9% |
| 2018 Q4 | -7.37 Million EUR | 0.0% |
| 2018 Q3 | -7.37 Million EUR | -3.94% |
| 2017 FY | -28.4 Million EUR | 5.97% |
| 2017 Q4 | -7.34 Million EUR | 0.0% |
| 2017 Q1 | -6.85 Million EUR | 4.58% |
| 2017 Q2 | -6.85 Million EUR | 0.0% |
| 2017 Q3 | -7.34 Million EUR | -7.21% |
| 2016 Q4 | -7.18 Million EUR | 0.0% |
| 2016 Q3 | -7.18 Million EUR | 9.31% |
| 2016 Q1 | -7.92 Million EUR | -17.14% |
| 2016 FY | -30.2 Million EUR | -16.34% |
| 2016 Q2 | -7.92 Million EUR | 0.0% |
| 2015 FY | -25.96 Million EUR | -70.78% |
| 2015 Q2 | -6.22 Million EUR | 0.0% |
| 2015 Q4 | -6.76 Million EUR | 0.0% |
| 2015 Q3 | -6.76 Million EUR | -8.68% |
| 2015 Q1 | -6.22 Million EUR | -46.45% |
| 2014 Q4 | -4.24 Million EUR | 0.0% |
| 2014 FY | -15.2 Million EUR | -10.39% |
| 2014 Q1 | -3.35 Million EUR | 13.32% |
| 2014 Q2 | -3.35 Million EUR | 0.0% |
| 2014 Q3 | -4.24 Million EUR | -26.67% |
| 2013 Q2 | -3.01 Million EUR | 0.0% |
| 2013 Q3 | -3.86 Million EUR | -28.26% |
| 2013 Q4 | -3.86 Million EUR | 0.0% |
| 2013 FY | -13.77 Million EUR | -29.77% |
| 2013 Q1 | -3.01 Million EUR | 0.0% |
| 2012 FY | -10.61 Million EUR | -9.23% |
| 2011 FY | -9.71 Million EUR | -1.32% |
| 2010 FY | -9.58 Million EUR | -15.57% |
| 2009 FY | -8.29 Million EUR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Boiron SA | 42.29 Million EUR | 131.755% |
| Laboratorios Farmaceuticos Rovi, S.A. | 220.25 Million EUR | 106.097% |
| Vetoquinol SA | 74.26 Million EUR | 118.083% |
| Valneva SE | -82.08 Million EUR | 83.641% |
| Nanobiotix S.A. | -26.77 Million EUR | 49.852% |
| PHAXIAM Therapeutics S.A. | -23.66 Million EUR | 43.242% |
| Vivoryon Therapeutics N.V. | -28.83 Million EUR | 53.431% |
| BioSenic S.A. | -7.04 Million EUR | -90.753% |
| ABIVAX Société Anonyme | -127.37 Million EUR | 89.457% |
| Formycon AG | -369 Thousand EUR | -3539.295% |